Feng Shen1, Yu-Qiang Mi2, Liang Xu2, Yong-Gang Liu2, Xiao-Ying Wang3, Qin Pan1, Rui-Nan Zhang1, Xi-Qi Hu4, Lei-Ming Xu1, Jian-Gao Fan1,5. 1. Department of Gastroenterology, Center for Fatty Liver, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 2. Research Institute of Liver Diseases, Tianjin Second People's Hospital, Tianjin, China. 3. Department of Pathology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 4. Department of Pathology, Shanghai Medical College of Fudan University, Shanghai, China. 5. Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China.
Abstract
BACKGROUND: Liver stiffness measurement (LSM) by transient elastography is a noninvasive method for the diagnosis of hepatic fibrosis. The impact of hepatic steatosis on LSM remains to be explored. AIM: To determine whether LSM is affected by hepatic steatosis in patients with chronic hepatitis B (CHB). METHODS: Consecutive patients with biopsy-proven CHB were prospectively enrolled. Hepatic steatosis was classified by pathology as none (S0, <5%), mild (S1, 5%-33%), and moderate-severe (S2-3, >33%), and quantitatively by controlled attenuation parameter (CAP) as CAP S0 (≤247 dB/m), CAP S1 (248-267 dB/m) and CAP S2-3 (≥268 dB/m). Liver fibrosis was assessed by METAVIR classification and noninvasively by LSM. RESULTS: The prevalence of non-alcoholic fatty liver disease (n = 223) in CHB patients (n = 593) was 37.6%. Forty-eight belonged to S2-3 and 127 belonged to CAP S2-3. In patients without significant fibrosis (F0-1), the median LSM (kPa) was 7.4 in S2-3 and 7.1 in CAP S2-3, which was significantly higher than that in S0/S1 (P = 0.005) and CAP S0/S1 (P = 0.003). No significant difference was found in significant fibrosis (F2-4). For LSM identifying significant fibrosis (F2-4), the negative predictive value was higher in CHB patients with CAP ≥ 268 compared to those with CAP < 268 (0.81 vs 0.73); the positive predictive value was lower in CAP ≥ 268 than its counterpart (0.65 vs 0.76). CONCLUSIONS: Moderate-severe steatosis increased the LSM value in CHB patients without significant fibrosis. A CAP ≥ 268 did not affect LSM for ruling out, but it slightly affected LSM for ruling in significant fibrosis. TRIAL REGISTRATION: ChiCTR-DDT-13003983.
BACKGROUND:Liver stiffness measurement (LSM) by transient elastography is a noninvasive method for the diagnosis of hepatic fibrosis. The impact of hepatic steatosis on LSM remains to be explored. AIM: To determine whether LSM is affected by hepatic steatosis in patients with chronic hepatitis B (CHB). METHODS: Consecutive patients with biopsy-proven CHB were prospectively enrolled. Hepatic steatosis was classified by pathology as none (S0, <5%), mild (S1, 5%-33%), and moderate-severe (S2-3, >33%), and quantitatively by controlled attenuation parameter (CAP) as CAP S0 (≤247 dB/m), CAP S1 (248-267 dB/m) and CAP S2-3 (≥268 dB/m). Liver fibrosis was assessed by METAVIR classification and noninvasively by LSM. RESULTS: The prevalence of non-alcoholic fatty liver disease (n = 223) in CHB patients (n = 593) was 37.6%. Forty-eight belonged to S2-3 and 127 belonged to CAP S2-3. In patients without significant fibrosis (F0-1), the median LSM (kPa) was 7.4 in S2-3 and 7.1 in CAP S2-3, which was significantly higher than that in S0/S1 (P = 0.005) and CAP S0/S1 (P = 0.003). No significant difference was found in significant fibrosis (F2-4). For LSM identifying significant fibrosis (F2-4), the negative predictive value was higher in CHB patients with CAP ≥ 268 compared to those with CAP < 268 (0.81 vs 0.73); the positive predictive value was lower in CAP ≥ 268 than its counterpart (0.65 vs 0.76). CONCLUSIONS: Moderate-severe steatosis increased the LSM value in CHB patients without significant fibrosis. A CAP ≥ 268 did not affect LSM for ruling out, but it slightly affected LSM for ruling in significant fibrosis. TRIAL REGISTRATION: ChiCTR-DDT-13003983.
Authors: Jie Chen; Alina M Allen; Terry M Therneau; Jun Chen; Jiahui Li; Safa Hoodeshenas; Jingbiao Chen; Xin Lu; Zheng Zhu; Sudhakar K Venkatesh; Bin Song; Richard L Ehman; Meng Yin Journal: Eur Radiol Date: 2021-08-25 Impact factor: 5.315
Authors: Mandana Khalili; Wendy C King; David E Kleiner; Mamta K Jain; Raymond T Chung; Mark Sulkowski; Mauricio Lisker-Melman; David K Wong; Marc Ghany; Arun Sanyal; Richard K Sterling Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 20.999
Authors: Mandana Khalili; David E Kleiner; Wendy C King; Richard K Sterling; Marc G Ghany; Raymond T Chung; Atul K Bhan; Philip Rosenthal; Mauricio Lisker-Melman; Rageshree Ramachandran; Anna S Lok Journal: Am J Gastroenterol Date: 2021-08-01 Impact factor: 12.045